Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease

Gut

Volumn 46, Issue SUPPL. 1, 2000, Pages

  Scott, E M ^a   Scott, B B ^b   Gaywood, I ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b LINCOLN COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; STEROID; VITAMIN D;

AGING; ALCOHOL CONSUMPTION; BONE DENSITY; CELIAC DISEASE; CORTICOSTEROID THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; EXERCISE; FRACTURE; GLUTEN FREE DIET; HORMONE SUBSTITUTION; OSTEOPOROSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SMOKING;

BONE DENSITY; CALCITONIN; CELIAC DISEASE; DENSITOMETRY; DIPHOSPHONATES; EXERCISE; FRACTURES, SPONTANEOUS; HUMANS; INFLAMMATORY BOWEL DISEASES; OSTEOPOROSIS; SEX FACTORS; STEROIDS; VITAMIN D;

EID: 0034066384     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. 1 Melton LJ, Chrischilles EA, Cooper C, et al. How many women have osteoporosis? J Bone Miner Res 1992;9:1005-10.
2. 2 Department of Health. Report of the advisory group on osteoporosis. London: HMSO, 1994.
3. 3 WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Post Menopausal Osteoporosis. Assessment of fracture risk and its application to screening for post menopausal osteoporosis: report of a WHO study group. (WHO technical series 843.) Geneva: WHO, 1994.
4. 4 Melton LJ, Atkinson EJ, O'Fallon WM, et al. Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites? J Bone Miner Res 1991;6(suppl 1):S136.
5. 5 Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-5.
6. 6 Porter RW, Miller CG, Grainger D, et al. Prediction of hip fracture in elderly women: a prospective study. BMJ 1990; 301:638-41.
7. 7 Lotz JC, Gerhart TN, Hayes WC. Mechanical properties of trabecular bone from the proximal femur: a quantitative CT study. J Comput Assist Tomogr 1990;14:107-14.
8. 8 Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
9. 9 Anonymous. Screening for osteoporosis to prevent fractures: bulletin on the effectiveness of health services intervention for decision makers. Vol 1. London School of Public Health, University of Leeds, Centre for Health Economics, University of York, Research Unit of the Royal College of Physicians, Department of Health, 1992.
10. 10 Sheldon TA, Raffle A, Watt I. Department of Health shoots itself in the hip. BMJ 1996;312:296-8.
11. 11 Compston JE, Cooper C, Kanis JA. Bone densitometry in clinical practice. BMJ 1995;310:1507-10.
12. 12 McCloskey EV, Murray SA, Miller C, et al. Broadband ultrasound attenuation in the os calcis: relationship to bone mineral at other skeletal sites. Clin Sci 1990;78:227-33.
13. 13 McCloskey EV, Murray SA, Charlesworth D, et al. Assessment of broadband ultrasound attenuation in the os calcis in vitro. Clin Sci 1990;78:221-5.
14. 14 Caraceni MP, Molteni N, Bardella MT, et al. Bone and mineral metabolism in adult celiac disease. Am J Gastroenterol 1988;83:274-7.
15. 15 Molteni N, Caraceni MP, Bardella MT, et al. Bone mineral density in adult celiac patients and the effect of gluten-free diet from childhood. Am J Gastroenterol 1990;85:51-3.
16. 16 Bode S, Hassager C, Gudmand-Hoyer E, et al. Body composition and calcium metabolism in adult treated coeliac disease. Gut 1991;32:1342-5.
17. 17 Mazure R, Vasquez H, Gonzalez D, et al. Bone mineral affection in asymptomatic adult patients with celiac disease. Am J Gastroenterol 1994;89:2130-4.
18. 18 Valdimarsson T, Toss G, Ross I, et al. Bone mineral density in coeliac disease. Scand J Gastroenterol 1994;29:457-61.
19. 19 McFarlane XA, Bhalla AK, Reeves DE, et al. Osteoporosis in treated adult coeliac disease. Gut 1995;36:710-14.
20. 20 Walters JRF, Banks LM, Butcher GP, et al. Detection of low bone mineral density by dual energy absorptiometry in unsuspected suboptimally treated coeliac disease. Gut 1995;37:220-4.
21. 21 Pistorius LR, Sweiden WH, Purdie DW, et al. Coeliac disease and bone mineral density in adult female patients. Gut 1995;37:639-42.
22. 22 Corazza GR, Sario AD, Cecchetti L, et al. Bone mass and metabolism in patients with celiac disease. Gastroenterology 1995;109:122-8.
23. 23 Valdimarsson T, Lofman O, Toss G, et al. Reversal of osteopenia with diet in adult coeliac disease. Gut 1996;38:322-7.
24. 24 Mora S, Weber G, Barera G, at al. Effect of gluten-free diet on bone mineral content in growing patients with celiac disease. Am J Clin Nutr 1993;57:224-8.
25. 25 McFarlane XA, Dixey J, Dumfrey J, et al. Increased risk of bone fractures in coeliac disease [abstract]. Gastroenterology 1996;110:A821.
26. 26 Walters JRF. Bone mineral density in coeliac disease. Gut 1994;35:150-1.
27. 27 Farthing MJ, Rees LJ, Edwards CRW, et al. Male gonadal function in coeliac disease. 2. Sex hormones. Gut 1983;24: 127-35.
28. 28 Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987;106:354-61.
29. 29 Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28: 410-15.
30. 30 Motley RJ, Crawley EO, Evans C, et al. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. Gut 1988;29:1332-6.
31. 31 Clements D, Motley RJ, Evans WD, et al. longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992;27:1055-60.
32. 32 Silvennoinen JA, Karttunen TJ, Niemela SE, et al. A controlled study of bone mineral density with inflammatory bowel disease. Gut 1995;37:71-6.
33. 33 Bischoff SC, Herrman A, Evers J, et al. Bone density and bone metabolism in inflammatory bowel disorders (TBD). A clinical study in 90 patients [abstract]. Gastroenterology 1996;110:A865.
34. 34 Lisciandrano D, Ranzi T, Ulivieri FM, et al. Bone mineral density in patients with ulcerative colitis [abstract]. Gastroenterology 1996;110:A951.
35. 35 Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997;40:313-19.
36. 36 Bjarnason I, Macpherson A, MacKintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228-33.
37. 37 Farthing MJG, Dawson AM. Impaired semen quality in Crohn's disease - drugs, ill health or undernutrition? Scand J Gastroenterol 1983;18:57-60.
38. 38 Schaison G, Durand F, Mowszowicz I. Effect of glucocorticoids on plasma testosterone in men. Acta Endocrinol (Copenh) 1978;89:126-31.
39. 39 MacAdams MR, White RH, Chipps BE. Reduction in serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1968;104:648-51.
40. 40 Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodelling - emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305-11.
41. 41 Tragone A, Mercuriali B, Vignola ML, et al. Bone mineral density and serum interleukin-6 (IL-6) concentration in patients with Crohn's disease [abstract]. Gastroenterology 1996;110:A1030.
42. 42 Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112: 352-64.
43. 43 American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-801.
44. 44 Liberman UA, Weiss SR, Broil J, et al. The effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
45. 45 Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
46. 46 Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women - The Framingham study. N Engl J Med 1987;317:1169-74.
47. 47 Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Arm Intern Med 1992;117:1-9.
48. 48 Clements D, Compston JE, Evans WD, et al. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993;34:1543-60.
49. 49 Christiansen C, Christiansen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/ gestagen therapy. Lancet 1981;i:459-61.
50. 50 Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16.
51. 51 Steinberg KK, Smith SJ, Thacker SB, et al. Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 1994;5:415-21.
52. 52 Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
53. 53 Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
54. 54 Storm T, Thomsborg G, Steinche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
55. 55 Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
56. 56 Reginster JY. Calcitonin for prevention and treatment of osteoporosis. Am J Med 1993;95:44-75.
57. 57 Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. BMJ 1992;305:556-61.
58. 58 Eastell R. Management of glucocorticoid-induced osteoporosis. J Intern Med 1995;237:439-47.
59. 59 Storm T, Kollerup G, Thomsborg G, et al. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 1996;23:1560-4.
60. 60 Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995;16;87-116.
61. 61 Greenberg GR, Feagan BC, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Gastroenterology 1996;110: 45-51.
62. 62 Messina OD, Barreira JC, Zanchetta JR, et al. Effect of low doses of deflazacort vs prednisolone on bone mineral content in premenopausal arthritis. J Rheumatol 1992;19: 1520-6.
63. 63 Hahn TJ, Halstead LR, Teitelbaum SL, et al. Altered mineral metabolism in glucocorticoid-induced osteopenia: effect of 25-hydroxyvitamin D administration. J Clin Invest 1979;64:655-65.
64. 64 DiMunno O, Boghe F, Favini P, et al. Prevention of glucocorticoid osteopenia: effect of oral 25-hydroxyvitamin D and calcium. Clin Rheumatal 1989;8:202-7.
65. 65 Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis - a comparison of calcium, calcitriol and calcitonin. N Engl J Med 1993;328:1747-52.
66. 66 Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996;125:961-8.
67. 67 Rickers H, Deding A, Christiansen C, et al. Corticosteroid-induced osteopenia and vitamin D metabolism: effect of Vitamin D2, calcium phosphate and sodium fluoride administration. Clin Endocrinol 1982;16:409-15.
68. 68 Braun JJ, Birkenhager-Frenkel DH, Rietveld JR, et al. Influence of 1a-(OH)D3 administration of bone and bone mineral metabolism in patients on chronic glucocorticoid treatment: a double blind controlled study. Clin Endocrinol 1983;19:265-73.
69. 69 Dykman TR, Haralson KM, Gluck OS, et al. Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984;27:1336-43.
70. 70 Bijlsma JWJ, Raymakers JA, Mosch C, et al. Effects of oral calcium and vitamin D on glucocorticoid osteopenia. Clin Exp Rheumatol 1988;6:113-19.
71. 71 Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid-induced osteoporosis: a 3 year follow-up. J Rheumatol 1996;23:995-1000.
72. 72 Marriott BM. Vitamin D supplementation: a word of caution. Ann Intern Med 1997;127:231-3.
73. 73 Vogelsang H, Ferenci P, Resch H, et al. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995;7:609-14.
74. 74 Dawson-Hughes B, Harris S, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-6.
75. 75 Reid IR, King AR, Alexander CJ, et al. Prevention of steroid induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988;i: 143-6.
76. 76 Adachi JD, Cranney A, Goldsmith CL, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid-induced bone loss. J Rheumatol 1994;21: 1922-6.
77. 77 Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33:348-50.
78. 78 Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235-42.
79. 79 Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
80. 80 Reid IR. Preventing glucocorticoid-induced osteoporosis. N Engl J Med 1997;337:420-1.
81. 81 Eastell R, Reid DM, Compston, J, et al. A UK consensus group of management of cortico-induced osteoporosis: an update. J Intern Med 1998;244:271-92.